EA200801731A1 - Составы и способы лечения тробмоцитемии - Google Patents

Составы и способы лечения тробмоцитемии

Info

Publication number
EA200801731A1
EA200801731A1 EA200801731A EA200801731A EA200801731A1 EA 200801731 A1 EA200801731 A1 EA 200801731A1 EA 200801731 A EA200801731 A EA 200801731A EA 200801731 A EA200801731 A EA 200801731A EA 200801731 A1 EA200801731 A1 EA 200801731A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trobmocythemia
compositions
treatment
methods
anagrelide
Prior art date
Application number
EA200801731A
Other languages
English (en)
Inventor
Ричард Франклин
Original Assignee
Шир Холдингз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801731(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шир Холдингз Аг filed Critical Шир Холдингз Аг
Publication of EA200801731A1 publication Critical patent/EA200801731A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Настоящее изобретение обеспечивает способ лечения или предотвращения тромбоцитемии у пациента, содержащий введение указанному пациенту эффективной дозы анагрелида или фармацевтически допустимой соли анагрелида способом, исключающим первичное попадание и метаболизм анагрелида в печени.
EA200801731A 2003-01-23 2004-01-23 Составы и способы лечения тробмоцитемии EA200801731A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44176503P 2003-01-23 2003-01-23

Publications (1)

Publication Number Publication Date
EA200801731A1 true EA200801731A1 (ru) 2009-10-30

Family

ID=32771969

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200801731A EA200801731A1 (ru) 2003-01-23 2004-01-23 Составы и способы лечения тробмоцитемии
EA200501166A EA010871B1 (ru) 2003-01-23 2004-01-23 Трансдермальные составы и способы лечения тромбоцитемии

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200501166A EA010871B1 (ru) 2003-01-23 2004-01-23 Трансдермальные составы и способы лечения тромбоцитемии

Country Status (29)

Country Link
US (1) US20040209907A1 (ru)
EP (1) EP1589973B2 (ru)
JP (1) JP4624978B2 (ru)
KR (1) KR20050111317A (ru)
CN (1) CN1738623A (ru)
AP (1) AP2103A (ru)
AT (1) ATE463246T1 (ru)
AU (1) AU2004206783B2 (ru)
BR (1) BRPI0406634A (ru)
CA (1) CA2513708C (ru)
CO (1) CO5640120A2 (ru)
CY (1) CY1110162T1 (ru)
DE (1) DE602004026405D1 (ru)
DK (1) DK1589973T4 (ru)
EA (2) EA200801731A1 (ru)
ES (1) ES2344062T5 (ru)
HK (1) HK1075844A1 (ru)
HR (1) HRP20050633A2 (ru)
IL (1) IL169153A (ru)
MX (1) MXPA05007287A (ru)
NO (1) NO330805B1 (ru)
OA (1) OA13018A (ru)
PL (1) PL377933A1 (ru)
PT (1) PT1589973E (ru)
RS (1) RS20050524A (ru)
SG (1) SG153661A1 (ru)
SI (1) SI1589973T2 (ru)
WO (1) WO2004064841A1 (ru)
ZA (1) ZA200506056B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813960B2 (en) * 2000-10-04 2020-10-27 Paul Edward Stamets Integrative fungal solutions for protecting bees and overcoming colony collapse disorder (CCD)
FR2870125B1 (fr) * 2004-05-12 2010-03-26 Dermaconcept Jmc Formulation du type spot-on utile en cosmetologie et en dermatologie
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
CN101534904B (zh) * 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
GB0623749D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
GB0623750D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
EP3054935B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
US11752182B2 (en) 2014-03-10 2023-09-12 Turtle Bear Holdings, Llc Integrative fungal solutions for protecting bees
CN107206000A (zh) * 2014-12-22 2017-09-26 阿鲁兹特拉生物有限公司 预防和治疗血小板增多的癌症患者中的转移性疾病
CN108776180B (zh) * 2018-03-20 2020-12-04 广西壮族自治区食品药品检验所 一种同时测定曲咪新乳膏中多种透皮吸收促进剂的检测方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862966A (en) * 1958-12-02 archo
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
JPS49132019A (ru) * 1973-02-26 1974-12-18
DE2400887A1 (de) * 1974-01-09 1975-08-28 Bayer Ag Verfahren zur herstellung von nitroderivaten aromatischer verbindungen
JPS5752352B2 (ru) * 1974-02-28 1982-11-06
US3983120A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3983119A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
JPS5251379A (en) * 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
JPS5291885A (en) * 1976-01-23 1977-08-02 Sumitomo Chem Co Ltd 3,4-dihydro-2(1h)-quinazolinone derivatives
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4208521A (en) * 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
US4357330A (en) * 1981-07-30 1982-11-02 Bristol-Myers Company Pharmaceutical compositions
US4444777A (en) * 1981-07-30 1984-04-24 Bristol-Myers Company Pharmaceutical compositions of anagrelide and sulfinpyrazone
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
EP0244525B1 (en) * 1986-05-08 1990-07-25 International Business Machines Corporation Disk file with air filtration system
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH088287Y2 (ja) 1988-02-22 1996-03-06 日産自動車株式会社 Ｄｏｈｃ４バルブ型内燃機関のシリンダヘッド
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5043327A (en) * 1989-07-18 1991-08-27 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
US5232702A (en) 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
AU3071492A (en) * 1991-11-15 1993-06-15 University Of Pennsylvania Suppression of megakaryocytopoiesis by neutrophil activating peptide-2
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US6024975A (en) * 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
JP3799502B2 (ja) * 1992-12-07 2006-07-19 エル テー エス ローマン テラピー・システーメゲー．エム．ベー．ハー ウント コンパニー カー．ゲー 抗血栓治療および癌予防のためのアセチルサリチル酸を含有する経皮投与システム
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
JP2001500865A (ja) * 1996-09-13 2001-01-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 避妊の非ホルモン法
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU9621598A (en) * 1997-10-20 1999-05-10 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
US6156753A (en) † 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6493180B1 (en) * 1999-08-19 2002-12-10 Samsung Electronics Co., Ltd. Hard disk drive cover that contains a helmholtz resonator which attenuates acoustic energy
US6376242B1 (en) * 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
US6987640B2 (en) * 2000-07-26 2006-01-17 Seagate Technology Llc Two-part flow conditioning apparatus for a disc drive
US6388073B1 (en) * 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
AP2003002922A0 (en) * 2001-05-31 2003-12-31 Pharmacia Corp Skin-permeable selective cyclooxygenase-2 inhibitor composition.
US20030235609A1 (en) * 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030114673A1 (en) * 2002-05-29 2003-06-19 Lang Philip C. 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CA2572179A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases

Also Published As

Publication number Publication date
ES2344062T3 (es) 2010-08-17
ATE463246T1 (de) 2010-04-15
OA13018A (en) 2006-11-10
AP2005003362A0 (en) 2005-09-30
PL377933A1 (pl) 2006-02-20
DK1589973T4 (da) 2013-04-08
HRP20050633A2 (en) 2006-06-30
NO20053874D0 (no) 2005-08-18
IL169153A (en) 2011-01-31
DE602004026405D1 (de) 2010-05-20
CO5640120A2 (es) 2006-05-31
CA2513708A1 (en) 2004-08-05
US20040209907A1 (en) 2004-10-21
HK1075844A1 (en) 2005-12-30
DK1589973T3 (da) 2010-07-19
RS20050524A (en) 2007-11-15
EA010871B1 (ru) 2008-12-30
JP2006516563A (ja) 2006-07-06
MXPA05007287A (es) 2005-12-12
SG153661A1 (en) 2009-07-29
EP1589973A1 (en) 2005-11-02
CA2513708C (en) 2011-01-04
IL169153A0 (en) 2007-07-04
PT1589973E (pt) 2010-07-09
EP1589973B1 (en) 2010-04-07
AU2004206783A1 (en) 2004-08-05
AU2004206783B2 (en) 2009-03-26
JP4624978B2 (ja) 2011-02-02
EP1589973B2 (en) 2012-12-26
ZA200506056B (en) 2006-05-31
NO20053874L (no) 2005-10-19
EA200501166A1 (ru) 2006-02-24
BRPI0406634A (pt) 2005-12-06
WO2004064841A1 (en) 2004-08-05
KR20050111317A (ko) 2005-11-24
SI1589973T2 (sl) 2013-05-31
CN1738623A (zh) 2006-02-22
ES2344062T5 (es) 2013-04-26
AP2103A (en) 2010-02-08
SI1589973T1 (sl) 2010-08-31
CY1110162T1 (el) 2015-01-14
NO330805B1 (no) 2011-07-18

Similar Documents

Publication Publication Date Title
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
DK1658302T3 (da) Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
EA201490254A1 (ru) Комбинированное лечение гепатита с
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
MY143795A (en) Tetrahydropyridoindole derivatives
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
NO20064753L (no) Kombinasjonsterapi
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2002058535A3 (en) Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
TW200501958A (en) A therapeutic agent for treating a behavioral disorder